PMID- 22784304
OWN - NLM
STAT- MEDLINE
DCOM- 20130117
LR  - 20211021
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 12
DP  - 2012 Jul 11
TI  - Longitudinal MRI contrast enhanced monitoring of early tumour development with 
      manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) 
      in a CT1258 based in vivo model of prostate cancer.
PG  - 284
AB  - BACKGROUND: Cell lines represent a key tool in cancer research allowing the 
      generation of neoplasias which resemble initial tumours in in-vivo animal models. 
      The characterisation of early tumour development is of major interest in order to 
      evaluate the efficacy of therapeutic agents. Magnetic resonance imaging (MRI) 
      based in-vivo characterisation allows visualisation and characterisation of 
      tumour development in early stages prior to manual palpation. Contrast agents for 
      MRI such as superparamagnetic iron oxide nanoparticles (SPIOs) and manganese 
      chloride (MnCl2) represent powerful tools for the in-vivo characterisation of 
      early stage tumours. In this experimental study, we labelled prostate cancer 
      cells with MnCl2 or SPIOs in vitro and used 1 T MRI for tracing labelled cells 
      in-vitro and 7 T MRI for tracking in an in-vivo animal model. METHODS: Labelling 
      of prostate cancer cells CT1258 was established in-vitro with MnCl2 and SPIOs. 
      In-vitro detection of labelled cells in an agar phantom was carried out through 
      1 T MRI while in-vivo detection was performed using 7 T MRI after subcutaneous 
      (s.c.) injection of labelled cells into NOD-Scid mice (n = 20). The animals were 
      scanned in regular intervals until euthanization. The respective tumour volumes 
      were analysed and corresponding tumour masses were subjected to histologic 
      examination. RESULTS: MnCl2in-vitro labelling resulted in no significant 
      metabolic effects on proliferation and cell vitality. In-vitro detection-limit 
      accounted 105 cells for MnCl2 as well as for SPIOs labelling. In-vivo 7 T MRI 
      scans allowed detection of 103 and 104 cells. In-vivo MnCl2 labelled cells were 
      detectable from days 4-16 while SPIO labelling allowed detection until 4 days 
      after s.c. injection. MnCl2 labelled cells were highly tumourigenic in NOD-Scid 
      mice and the tumour volume development was characterised in a time dependent 
      manner. The amount of injected cells correlated with tumour size development and 
      disease progression. Histological analysis of the induced tumour masses 
      demonstrated characteristic morphologies of prostate adenocarcinoma. CONCLUSIONS: 
      To the best of our knowledge, this is the first study reporting direct in-vitro 
      MnCl2 labelling and 7 T based in-vivo MRI tracing of cancer cells in a model of 
      prostate cancer. MnCl2 labelling was found to be suitable for in-vivo tracing 
      allowing long detection periods. The labelled cells kept their highly 
      tumourigenic potential in-vivo. Tumour volume development was visualised prior to 
      manual palpation allowing tumour characterisation in early stages of the disease.
FAU - Sterenczak, Katharina A
AU  - Sterenczak KA
AD  - University of Veterinary Medicine Hannover, Hannover, Germany.
FAU - Meier, Martin
AU  - Meier M
FAU - Glage, Silke
AU  - Glage S
FAU - Meyer, Matthias
AU  - Meyer M
FAU - Willenbrock, Saskia
AU  - Willenbrock S
FAU - Wefstaedt, Patrick
AU  - Wefstaedt P
FAU - Dorsch, Martina
AU  - Dorsch M
FAU - Bullerdiek, Jorn
AU  - Bullerdiek J
FAU - Murua Escobar, Hugo
AU  - Murua Escobar H
FAU - Hedrich, Hans
AU  - Hedrich H
FAU - Nolte, Ingo
AU  - Nolte I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120711
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Chlorides)
RN  - 0 (Contrast Media)
RN  - 0 (Ferric Compounds)
RN  - 0 (Magnetite Nanoparticles)
RN  - 0 (Manganese Compounds)
RN  - 1K09F3G675 (ferric oxide)
RN  - QQE170PANO (manganese chloride)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cell Survival
MH  - *Chlorides
MH  - *Contrast Media
MH  - Disease Models, Animal
MH  - *Ferric Compounds
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - *Magnetite Nanoparticles
MH  - Male
MH  - *Manganese Compounds
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Prostatic Neoplasms/*diagnosis/pathology
PMC - PMC3520113
EDAT- 2012/07/13 06:00
MHDA- 2013/01/18 06:00
PMCR- 2012/07/11
CRDT- 2012/07/13 06:00
PHST- 2011/12/02 00:00 [received]
PHST- 2012/06/26 00:00 [accepted]
PHST- 2012/07/13 06:00 [entrez]
PHST- 2012/07/13 06:00 [pubmed]
PHST- 2013/01/18 06:00 [medline]
PHST- 2012/07/11 00:00 [pmc-release]
AID - 1471-2407-12-284 [pii]
AID - 10.1186/1471-2407-12-284 [doi]
PST - epublish
SO  - BMC Cancer. 2012 Jul 11;12:284. doi: 10.1186/1471-2407-12-284.